Research Article
The Association of Thyroid Hormone Changes with Inflammatory Status and Prognosis in COVID-19
Table 5
Characteristics and laboratory parameters of patients who had died and survived from COVID-19.
| | Parameter | n | Median (min-max) | IQR | value |
| | Age | | Survived | 196 | 58 (21–94) | 18.5 | | | Exitus | 9 | 76 (57–87) | 13 | 0.001 |
| | Length of hospitalization | | Survived | 196 | 10.5 (2–116) | 9 | | | Exitus | 9 | 21 (7–51) | 11 | 0.006 |
| | Lymphocyte percent | | Survived | 196 | 19.2 (3.3–51.6) | 15.8 | | | Exitus | 9 | 12.3 (3.3–17.1) | 4.9 | 0.005 |
| | Neutrophil count (×103/μl) | | Survived | 196 | 3.6 (0.9–21.3) | 2.55 | | | Exitus | 9 | 5.2 (3.1–11) | 44 | 0.004 |
| | Thrombocyte count (×103/μL) | | Survived | 196 | 182 (36–562) | 82 | | | Exitus | 9 | 195 (130–327) | 128 | 0.39 |
| | Ferritin (μg/L) | | Survived | 190 | 166 (5.3–2770) | 351 | | | Exitus | 9 | 147 (34.4–985) | 303 | 0.9 |
| | LDH (U/L) | | Survived | 195 | 261 (126–979) | 137 | | | Exitus | 9 | 300 (165–589) | 83 | 0.11 |
| | hs-CRP (mg/L) | | Survived | 196 | 31.8 (1–289) | 70.5 | | | Exitus | 9 | 61.1 (12.7–317) | 176 | 0.056 |
| | Procalcitonin (μg/L) | | Survived | 191 | 0.08 (0.02–2.47) | 0.08 | | | Exitus | 9 | 0.13 (0.07–20.5) | 0.03 | 0.02 |
| | D-dimer (mg/L) | | Survived | 195 | 0.63 (0.15–20) | 0.74 | | | Exitus | 9 | 1.68 (0.6–7.15) | 1.49 | 0.0053 |
| | TSH (mU/L) | | Survived | 196 | 1.22 (0.09–6.26) | 1.27 | | | Exitus | 9 | 0.5 (0.08–2.46) | 0.85 | 0.02 |
| | FT4 (ng/dL) | | Survived | 192 | 0.97 (0.46–1.84) | 0.26 | | | Exitus | 9 | 1.04 (0.61–1.51) | 0.64 | 0.82 |
| | FT3 (ng/L) | | Survived | 191 | 2.57 (0.23–5.3) | 0.81 | | | Exitus | 9 | 1.69 (1.01–3.3) | 1.03 | 0.0025 |
|
|
LDH: lactate dehydrogenase; CRP: C-reactive protein; LDH: lactate dehydrogenase; TSH: thyroid-stimulating hormone; FT4: free thyroxine; FT3: free triiodothyronine; IQR: interquartile range.
|
